Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Send this study to a contact
1
Your personal information
Your name
Your e-mail
Send me a copy
2
Your recipient's information
The name of your contact
Your contact email
3
Your message
Votre message
An Open Label, Multicentre, Single Arm Study to Characterise the Efficacy, Safety and Tolerability of Gefitinib 250 mg (IRESSA™) as First line Treatment in Caucasian Patients, who have Epidermal Growth Factor Receptor (EGFR) Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) https://kusajili.com:443/Trial/Fyqdtea0zE-kp4f1-5EtnA%24an-open-label-multicentre-single-arm-study-to-characterise-the-efficacy-safety-and-tolerability-of-gefitinib-250-mg-iressat-as-
I have read and accept the terms of use of the site and the Privacy Policy
Send your message